Anthony Mariano, PhD, gives insight into dealing with patients' demands for opioids.
Increasing evidence supports the notion that an individual's specific response to pain or pain treatments may be affected by particular gene polymorphisms.
An interview with Penney Cowan, founder and chief executive officer of the American Chronic Pain Association, where she discusses the ACPA's publication aimed at helping healthcare practitioners improve care of patients with chronic pain.
The National Academies of Sciences, Engineering, and Medicine has released a report on cannabis and cannabinoids, outlining current knowledge and giving recommendations for future research.
The updated guidelines address guidance on dosing, including reduced starting and maintenance dosing, and safety precautions for diagnosing and treating complications.
Chronic pain management is dependent on the continuous assessment of pain to determine the effectiveness of the treatment.
Researchers have developed a new self-reported pain scale utilizing more detailed descriptions of patient activity patterns
Cannabis-related poison control calls and hospital discharges spike with wider availability.
Are we overestimating the efficacy of step III analgesics?
OA affects over 20 million Americans and is most prevalent among the elderly, causing potentially debilitating symptoms of muscle weakness, pain, and joint stiffness.
A review and meta-analysis indicates that spinal manipulative therapy is linked to modest improvements in low back pain.
The Veterans Administration and Department of Defense issue an updated clinical practice guideline regarding opioid therapy for chronic pain in veterans.
Researchers found a correlation between use of corticosteroids and increased odds of metabolic syndrome and elevated body mass index.
FDA gives breakthrough therapy designation to rituxan for treatment of pemphigus vulgaris and is indicated for treating rheumatoid arthritis
A training program on opioid prescribing for general practice registrars was developed to improve adherence to guidelines on opioid prescribing for chronic noncancer pain.
A single glucocorticoid intradiscal injection will reduce chronic low back pain with active discopathy for 1 month but not 12 months after injection.
New opioid analgesic, NKTR-181, being evaluated in the SUMMIT-07 Phase 3 study for the treatment of moderate to severe chronic pain.
Researchers found that prescribing opioids to patients for 8 or more days increases likelihood of long-term dependence.
Study examines cohort of consecutive patients treated with 3D neural targeting spinal cord stimulation vs patients previously treated with a traditional SCS device.
Heroin accounted for one-quarter of overdose deaths in 2015.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care